AnteoTech Strengthens Funding to Accelerate Global Commercialisation

AnteoTech Ltd (ASX: ADO) has completed a placement raising AU$3.5 million to accelerate the commercialisation of its Life Sciences and Advanced Battery Technology platforms. The capital raise was strongly supported by institutional, sophisticated, and professional investors and completed at an issue price of AU$0.0155 per share, with the placement scaled back due to demand. Upon completion, the Company’s pro forma cash balance is expected to be approximately AU$6.6 million. Funds are expected to support revenue growth initiatives, customer trial conversions, and strategic partnership development across global markets, with a focus on advancing near-term commercial opportunities in Life Sciences, battery technologies, and emerging applications.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au